Cyclic guanosine monophosphate pathway effectors in retinal photoreceptors (cGMP effectors)

The cGMP pathway effectors in retinal photoreceptors, primarily comprising cyclic nucleotide-gated (CNG) channels and cGMP-dependent protein kinase (PKG), are central to the visual transduction process and the pathophysiology of retinal degeneration (Paquet-Durand et al., 2019). In a healthy state, cGMP levels are precisely regulated to gate CNG channels, allowing the influx of sodium and calcium ions that maintain the dark current necessary for light detection (Arango-Gonzalez et al., 2014). In many inherited retinal dystrophies, such as retinitis pigmentosa, mutations in genes like PDE6 lead to a toxic accumulation of cGMP, which over-activates PKG and CNG channels, ultimately triggering photoreceptor cell death (Power et al., 2020). Therapeutic strategies targeting these effectors include the use of inhibitory cGMP analogs to suppress PKG activity or channel blockers to limit calcium-induced toxicity (Vighi et al., 2018). These approaches aim to decouple the genetic mutation from the degenerative pathway, providing a mutation-independent treatment for blindness.

Other names

Phototransduction cGMP effectorsRetinal cGMP signaling componentsPKG and CNG channelscGMP-dependent signaling pathway

Inhibition of cGMP-dependent protein kinase (PKG) to prevent pro-apoptotic signaling; Blockade or modulation of cyclic nucleotide-gated (CNG) channels to reduce toxic cation influx.